Kopran Limited (KOPRAN) announced the successful completion of a GMP inspection by the European Union Medicines Authority at its Formulation manufacturing facility in Khopoli. The inspection, conducted from September 18 to September 23, 2026, concluded with no critical observations, one major observation, and some minor observations. Notably, there were no data integrity related observations. The company is currently preparing compliance responses to the EU authorities, expected to be submitted within a fortnight.

Inspection Details

The Medicine Authority European Union (EU) inspected the Khopoli facility to ensure compliance with Good Manufacturing Practices (GMP). The team evaluated various aspects of the manufacturing process, including quality control, production, and documentation. The inspection was thorough and comprehensive, covering all critical areas of the facility.

Compliance and Future Steps

Kopran Limited is in the process of addressing the minor and major observations noted during the inspection. The company is committed to maintaining the highest standards of manufacturing and will submit the required compliance responses to the EU authorities by October 2026. This proactive approach ensures that the facility continues to meet stringent regulatory requirements.

As a result, Kopran Limited reaffirms its dedication to quality and compliance, which is essential for its reputation and continued success in the pharmaceutical industry.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Kopran Limited

Kopran Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Kopran gains 33.2% over three months and trades near its 52-week highs. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. 1 loss quarter(s) over five years signals earnings fragility — not chronic but worth noting. Buyers show up with 5.0x the volume of sellers. Moreover, they dominated on 18 of recent sessions versus 12 for sellers — a healthy accumulation pattern. The stock rises 33.2% in three months. Yet revenue grows at only 7.2% and the PEG stands at 99.00. Either the market prices in a turnaround that has not shown up yet, or this is momentum without substance. Check the next two earnings prints before drawing conclusions. Check Fundamentals of Kopran Limited.

Sai Parenterals Limited (NSE: SAIPARENT) has completed the acquisition of a 60% equity stake in Prathyak Laboratories Private Limited for Rs. 15 crore, funded from the unutilised net proceeds of the Company’s initial public offering. This acquisition replaces the greenfield research centre the Company had originally intended to build. Prathyak Laboratories, now renamed as Sai Prathyak Laboratories Private Limited, has been in operation for three years and brings 28 research scientists and a development pipeline of 150 SKUs across 86 molecules. The acquisition provides Sai Parenterals with immediate access to a fully operational R&D facility, significantly accelerating its development work and reducing the time and effort required to assemble a scientific team.

Strategic Benefits of the Acquisition

The acquisition of an operating R&D platform rather than constructing one allows development work to begin immediately. It removes the construction cycle and, more significantly, the considerably harder task of assembling a scientific team of this calibre, which would have slowed the pace of a greenfield build. Prathyak’s development work supports the Company’s injectable programme directly. Formulations developed at this R&D centre can be taken into commercial production as the Company’s injectable capacity is expanded and upgraded, shortening the path from development to supply in regulated and semi-regulated markets.

Future Plans and Expansion

The residual 40% may be acquired through a Right of First Refusal (ROFR) at the same valuation as the present transaction, to be funded from internal accruals, taking Prathyak to a wholly owned position. Commenting on the acquisition, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, said: ‘Building a research centre from the ground up would have cost us a construction cycle and, far more significantly, the time taken to assemble a scientific team. Prathyak gives us both on day one — 28 research scientists who have worked together for three years, and a pipeline of 150 SKUs across 86 molecules in exactly the complex injectable and oncology areas we are building towards. The value of this acquisition lies in what it enables elsewhere in the Group. Work already completed at this R&D centre can be taken into production as our injectable capacity is expanded. The same R&D team will also develop the new products we are required to launch each year under our Australian agreements. We have acquired 60% today and will move to full ownership at the same valuation. This is a further step in the growth plan we set out at the time of our listing: deeper integration across our own value chain, a faster route from development to commercial supply, and capability built inside the Group instead of with third parties. We will continue to pursue opportunities of this kind, organic and inorganic, that strengthen the platform and create lasting value for our stakeholders.’

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sai falls 15.3% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 126.1% and profits at 111.8% CAGR. Both numbers are exceptional. The stock gains 0.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Both the business and the stock move in the right direction. Revenue grows at 126.1%, profits at 111.8%, and the PEG sits at 0.99 — below its growth rate. That combination is rare. Check Fundamentals of Sai Parenterals Limited.

Sai Parenterals Limited, an integrated CDMO and branded generics enterprise, announced that its Australian subsidiary, Noumed Pharmaceuticals Pty Ltd, has renewed its OTC Medicines Supply Agreement with one of Australia’s leading pharmacy chains. The renewal, valued at AUD 30 million (approximately INR 204 crore), extends for three years, enhancing the product portfolio and agreement tenure.

Expanded Product Portfolio

The agreement is projected at AUD 30 million over three years, translating to AUD 10 million annually. Noumed will manage the full value chain, including manufacturing, regulatory compliance, and distribution. The renewal signifies a continuous growth strategy with new product development and line extensions planned over the agreement term.

Strategic Growth and Market Positioning

For Sai Parenterals, the renewal improves the utilization of its regulatory and manufacturing infrastructure, strengthens earnings visibility, and provides a platform for expansion into additional regulated international markets. The agreement further cements Noumed’s position in the Australian OTC market, reflecting the trust in its regulatory, quality, and supply-chain capabilities.

As the Adelaide facility commissions and Indian capacity expands, production will move in-house, converting distribution margins into manufacturing margins on the same contracted revenue. This long-term agreement demonstrates the distinct advantage of Sai Parenterals’ CDMO platform, securing long-term revenue certainty and showcasing the company’s capabilities.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the Healthcare › Drug Manufacturers – General sector. Here’s a quick read on where the business and the stock stand today.

Sai posts a 20.3% three-month gain, but softens in the last few weeks. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 126.1% and profits at 111.8% CAGR. Both numbers are exceptional. The stock gives back 2.5% in the last month despite a positive three-month run. As a result, the earlier momentum appears to be fading. Both the business and the stock move in the right direction. Revenue grows at 126.1%, profits at 111.8%, and the PEG sits at 1.15 — below its growth rate. That combination is rare. Check Fundamentals of Sai Parenterals Limited.